Document is current

Documents that mention this clinical trial

47 A tumor-targeting IL-12 immunocytokine therapy in patients with advanced solid tumors increases peripheral natural killer (NK) cells with phenotypes associated with increased tumor cell lysis
https://doi.org/10.1136/jitc-2025-sitc2025.0047

1063 Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12
https://doi.org/10.1136/jitc-2023-sitc2023.1063

168 Increases in peripheral memory T cells with self-renewing properties in patients with advanced solid tumors treated with tumor-targeting IL-12 immunocytokine therapy
https://doi.org/10.1136/jitc-2025-sitc2025.0168

Generation and <i>in vivo</i> validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody
https://doi.org/10.1136/jitc-2022-005282

Documents that mention this clinical trial

47 A tumor-targeting IL-12 immunocytokine therapy in patients with advanced solid tumors increases peripheral natural killer (NK) cells with phenotypes associated with increased tumor cell lysis
https://doi.org/10.1136/jitc-2025-sitc2025.0047

1063 Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12
https://doi.org/10.1136/jitc-2023-sitc2023.1063

168 Increases in peripheral memory T cells with self-renewing properties in patients with advanced solid tumors treated with tumor-targeting IL-12 immunocytokine therapy
https://doi.org/10.1136/jitc-2025-sitc2025.0168

Generation and <i>in vivo</i> validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody
https://doi.org/10.1136/jitc-2022-005282